qlc1101
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2024 (NCT06403735)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06949761 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06980909 | Phase 1 | Jun 30, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06403735 | Phase 1 | Apr 25, 2024 | Qilu Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1